Galip Nilufer, Bahceciler Nerin
Division of Pediatric Allergy & Clinical Immunology, Near East University Hospital, Near East Avenue, Nicosia, North Cyprus, Mersin 10 Turkey.
Immunotherapy. 2015;7(12):1235-9. doi: 10.2217/imt.15.88. Epub 2015 Oct 2.
Sublingual route, a noninjective way of allergen administration appears to be associated with a lower incidence of severe systemic reactions compared with the subcutaneous route. Local adverse reactions are reported which resolve spontaneously within a few days without need for discontinuation of treatment. Hereby, we report two pediatric cases, one with persistent asthma and the other one with persistent allergic rhinitis. Both were treated by house dust mite sublingual immunotherapy, one of whom developed severe wheezing (grade 2 systemic reaction based on World Allergy Organization subcutaneous systemic reaction grading system) and the other intractable vomiting (grade 3 local reaction based on World Allergy Organization sublingual immunotherapy local adverse events grading system) at the end of the build-up phase which repeated on re-administration of the same dose. Both of those two cases completed their 3-year immunotherapy successfully by patient-based adjustment of the highest tolerated dose of the maintenance.
与皮下注射途径相比,舌下途径作为一种非注射的过敏原给药方式,似乎与严重全身反应的发生率较低相关。有局部不良反应的报道,这些反应在几天内可自行缓解,无需中断治疗。在此,我们报告两例儿科病例,一例患有持续性哮喘,另一例患有持续性过敏性鼻炎。两例均接受屋尘螨舌下免疫治疗,其中一例在剂量递增阶段结束时出现严重喘息(根据世界过敏组织皮下全身反应分级系统为2级全身反应),另一例出现顽固性呕吐(根据世界过敏组织舌下免疫治疗局部不良事件分级系统为3级局部反应),再次给予相同剂量时上述症状复发。通过基于患者调整维持期最高耐受剂量,这两例患者均成功完成了3年的免疫治疗。